ImClone Systems
Article Abstract:
The price appreciation potential of the shares of ImClone Systems Inc. for the years 2010-2012 is discussed. The New York, New York-based company offers novel cancer treatments using three promising strategies, growth factor inhibitors, cancer vaccines, and angiogenesis inhibitors.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2007
Pharmaceutical preparations, Evaluation, Pharmaceutical industry, Stocks, Stock prices
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
ImClone Systems
Article Abstract:
A comparative analysis of the company sales and earnings and the financial details of ImClone Systems from 1990 - 2003 are illustrated. Projections of the equity price of this company for 2004 - 2005 is made using Value Line estimates.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004
United States, Sales, profits & dividends, Company sales and earnings, Company earnings/profit
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: United States, Securities, Company securities, ImClone Systems Inc., Diagnostic reagents industry, IMCL
Similar abstracts:
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.